Diseases, Conditions, Syndromes

Blood tests can predict the risk of liver cirrhosis

Repeated measurements of the biomarker FIB-4 in the blood every few years can predict the risk of developing severe liver disease, according to a new study from Karolinska Institutet published in the Journal of Hepatology. ...

Diseases, Conditions, Syndromes

Universal gut microbiome-derived signature predicts cirrhosis

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease worldwide, affecting an estimated one-quarter of the global population. It is a progressive condition that, in worst cases, can lead to ...

Diseases, Conditions, Syndromes

Strength training benefits patients with cirrhosis

Three hours of weekly strength training combined with protein supplements leads to both bigger and stronger muscles in patients with cirrhosis. This is shown by a new study from Aarhus University and Aarhus University Hospital.

Diseases, Conditions, Syndromes

Hospitalizations for chronic liver disease on the rise

(HealthDay)—Hospitalizations for chronic liver disease (CLD) increased from 2012 to 2016, reaching a total estimated national cost of $81.1 billion, according to a study published online April 2 in JAMA Network Open.

Diseases, Conditions, Syndromes

Mavyret approved as 8-week treatment for hep C, compensated cirrhosis

(HealthDay)—Approval of Mavyret (glecaprevir and pibrentasvir) tablets has been expanded to eight-week treatment for treatment-naive patients aged 12 years and older with chronic hepatitis C virus (HCV) genotypes 1 through ...

Diseases, Conditions, Syndromes

FDA approves mavyret for children, adolescents with hep C

(HealthDay)—Mavyret (glecaprevir and pibrentasvir) tablets are now approved to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17 years, the U.S. Food and Drug Administration announced yesterday.

page 6 from 17